Drug Profile
Research programme: thromboses therapeutics - Ajinomoto
Alternative Names: AJP-117510Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ajinomoto
- Class
- Mechanism of Action Integrin alpha2beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in Japan
- 01 Apr 2006 Preclinical trials in Thrombosis in Japan (unspecified route)